Renal Cell Carcinoma

>

Latest News

Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens

November 28th 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.

Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment
Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment

November 24th 2023

Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC
Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC

November 16th 2023

Challenges Remain Despite Early Promises for CAR T-Cell Therapy in Advanced RCC
Challenges Remain Despite Early Promises for CAR T-Cell Therapy in Advanced RCC

November 11th 2023

Understanding Clonal Hematopoiesis in Kidney Cancer Could Improve Cardiovascular Outcomes
Understanding Clonal Hematopoiesis in Kidney Cancer Could Improve Cardiovascular Outcomes

November 11th 2023

Video Series
Video Interviews
Podcasts

More News